SEARCH

SEARCH BY CITATION

References

  • 1
    Constitution of the World Health Organization. Handbook of basic documents. Geneva: Palais des Nations, World Health Organization, 1952:320.
  • 2
    Schipper H, Clinch J, Olweny CLM. Quality of life studies: definitions and conceptual issues. In: SpilkerB, editor. Quality of life and pharmacoeconomics in cinical trial. Philadelphia, PA: Lippincot-Raven Press, 1990:1123.
  • 3
    Isolauri E, Huurre A, Salminem S, Impivaara O. The allergy epidemic extends beyond the past two decades. Clin Exp Allergy 2004;34:10071010.
  • 4
    Baiardini I, Braido F, Brandi S, Canonica GW. Allergic diseases and their impact on quality of life. Ann Allergy Asthma Immunol 2006;97:419428.
  • 5
    Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO workshop report. Bethesda, MD: National Institute of Health. NIH Publication number 02–3659, 2002; http://www.ginasthma.com; accessed 6 February 2008.
  • 6
    Bousquet J, Van Cauwenberge PB, Khaltaev N, ARIA Workshop Group, WHO. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S1S334.
  • 7
    Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 1994;94:182188.
  • 8
    Meltzer EO, Casale TB, Nathan RA, Thompson AK. Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1999;83:311317.
  • 9
    Majani G, Baiardini I, Giardini A. Health-related quality of life in young adults with seasonal allergic rhinitis. Allergy 2001;56:313317.
  • 10
    Stuck BA, Czaijkowski J, Hagner AE, Klimek L, Verse T, Hörmann K et al. Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial. J Allergy Clin Immunol 2004;113:663668.
  • 11
    Bousquet J, Neukirch F, Bousquet PJ, Gehano P, Klossek JM, Le Gal M et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006;117:158162.
  • 12
    Hyo S, Fujieda S, Kawada R, Kitazawa S, Takenaka H. The efficacy of short-term administration of 3 antihistamines vs placebo under natural exposure to Japanese cedar pollen. Ann Allergy Asthma Immunol 2005;94:457464.
  • 13
    Berger W, Hampel F Jr, Bernstein J, Shah S, Sacks H, Meltzer EO. Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006;97:375381.
  • 14
    Corren J, Storms W, Bernstein J, Berger W, Nayak A, Sacks H, Azelastine Cetirizine Trial No. 1 (ACT 1) Study Group. Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. Clin Ther 2005;27:543553.
  • 15
    Hampel FC Jr, Ratner PH, Amar NJ, Van Bavel JH, Mohar D, Fairchild CJ et al. Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCl nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared with vehicle placebo. Allergy Asthma Proc 2006;27:202207.
  • 16
    Meltzer EO, Hampel FC, Ratner PH, Bernstein DI, Larsen LV, Berger WE et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2005;95:600606.
  • 17
    Berger W, Abelson MB, Gomes PJ, Beck M, Kimura S, Westbrook T et al. Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy. Ann Allergy Asthma Immunol 2005;95:361371.
  • 18
    Pasquali M, Baiardini I, Rogkakou A, Riccio AM, Gamalero C, Descalzi D et al. Levoceterizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. Clin Exp Allergy 2006;36:11611167.
  • 19
    Canonica GW, Bousquet J, Van Hammee G, Bachert C, Durham SR, Klimek L et al., XPERT Study Group. Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. Respir Med 2006;100:17061715. Epub. 24 May 2006.
  • 20
    Barnes ML, Ward JH, Fardon TC, Lipworth BJ. Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis. Clin Exp Allergy 2006;36:676684.
  • 21
    Potter PC, Paediatric Levocetirizine Study Group. Efficacy and safety of levocetirizine on symptoms and health-related quality of life of children with perennial allergic rhinitis: a double-blind, placebo-controlled randomized clinical trial. Ann Allergy Asthma Immunol 2005;95:175180.
  • 22
    De Blic J, Wahn U, Billard E, Alt R, Pujazon MC. Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pedriatr Allergy Immunol 2005;16:267275.
  • 23
    Bachert C, Bousquet J, Canonica GW, Durham SR, Klimek L, Mullol J et al., XPERT Study Group. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004;114:838844.
  • 24
    Meltzer EO, Jalowayski AA, Vogt K, Iezzoni D, Harris AG. Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. Ann Allergy Asthma Immunol 2006;96:363368.
  • 25
    Bhatia S, Baroody FM, DeTineo M, Naclerio RM. Increased nasal airflow with budesonide compared with desloratadine during the allergy season. Arch Otolaryngol Head Neck Surg 2005;131:223228.
  • 26
    Okubo K, Gotoh M, Shimada K, Ritsu M, Okuda M, Crawford B. Fexofenadine improves the quality of life and work productivity in Japanese patients with seasonal allergic rhinitis during the peak cedar pollinosis season. Int Arch Allergy Immunol 2005;136:148154. Epub. 12 Jan 2005.
  • 27
    Bender BG, Milgrom H. Comparison of the effects of fluticasone propionate aqueous nasal spray and loratadine on daytime alertness and performance in children with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2004;92:344349.
  • 28
    Moinuddin R, DeTineo M, Maleckar B, Naclerio RM, Baroody FM. Comparison of the combinations of fexofenadine–pseudoephedrine and loratadine–montelukast in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2004;92:7379.
  • 29
    Cordray S, Harjo JB, Miner L. Comparison of intranasal hypertonic dead sea saline spray and intranasal aqueous triamcinolone spray in seasonal allergic rhinitis. Ear Nose Throat J 2005;84:426430.
  • 30
    Kaiser HB, Liao Y, Diener P, Leahy MJ, Garcia J, Georges G. Triamcinolone acetonide and fluticasone propionate nasal sprays provide comparable relief of seasonal allergic rhinitis symptoms regardless of disease severity. Allergy Asthma Proc 2004;25:423428.
  • 31
    Magen E, Yosefy C, Viskoper RJ, Mishal J. Treatment of allergic rhinitis can improve blood pressure control. J Hum Hypertens 2006;20:888893. Epub. 7 Sep 2006.
  • 32
    Mucha SM, DeTineo M, Naclerio RM, Baroody FM. Comparison of montelukast and pseudoephedrine in the treatment of allergic rhinitis. Arch Otolaryngol Head Neck Surg 2006;132:164172.
  • 33
    Chen ST, Lu KH, Sun HL, Chang WT, Lue KH, Chou MC. Randomized placebo-controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2–6 yr. Pediatr Allergy Immunol 2006;17:4954.
  • 34
    Van Adelsberg J, Philip G, Pedinoff AJ, Meltzer EO, Ratner PH, Menten J et al., Montelukast Fall Rhinitis Study Group. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 2004;59:357.
  • 35
    Patel P, Philip G, Yang W, Call R, Horak F, LaForce C et al. Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis. Ann Allergy Asthma Immunol 2005;95:551557.
  • 36
    Philip G, Nayak AS, Berger WE, Leynadier F, Vrijens F, Dass SB et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 2004;20:15491558.
  • 37
    Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709717.
  • 38
    Passalacqua G, Pasquali M, Ariano R, Lombardi C, Giardini A, Baiardini I et al. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy 2006;61:849854.
  • 39
    Colas C, Monzon S, Venturini M, Lezaun A. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule. J Allergy Clin Immunol 2006;117:810816. Epub. 8 Feb 2006.
  • 40
    Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802809.
  • 41
    Frew AJ, Powell RJ, Corrigan CJ, Durham SR, UK Immunotherapy Study Group. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319325.
  • 42
    Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005;116:608613.
  • 43
    Alexander C, Tarzi M, Larche M, Kay AB. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005;60:12691274.
  • 44
    Alvarez-Cuesta E, Aragoneses-Gilsanz E, Martin-Garcia C, Berges-Gimeno P, Gonzales-Mancebo E, Cuesta-Herranz J. Immunotherapy with depigmented glutaraldehyde-polymerized extracts: changes in quality of life. Clin Exp Allergy 2005;35:572578.
  • 45
    Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A, Study Group. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-absorbed six-grass pollen allergoid. Allergy 2005;60:801807.
  • 46
    FDA. Draft guidance for industry on patient-reported outcome measures: use in medicinal product development to support labeling claims, Fed Registe 2006;71:58625863.
  • 47
    Committee for Medicinal Products for Human Use. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products, 2005. http://www.emea.europa.eu/pdfs/human/ewp/1393104en.pdf (accessed 7 December 2006).
  • 48
    Bousquet PJ, Bousquet-Rouanet L, Co Minh HB, Urbinelli R, Allaert FA, Demoly P. ARIA (allergic rhinitis and its impact on asthma) classification of allergic rhinitis severity in clinical practice in France. Int Arch Allergy Immunol 2007;143:163169.
  • 49
    Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet 2006;368:733743.
  • 50
    Baiardini I, Braido F, Canonica GW. Sleep disturbances in allergic diseases. Allergy 2006;61:12591267.